THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Gene makeovers

To treat 2 rare disorders, firm uses defanged HIV virus to get ‘corrected’ genetic material into cells

By Karen Weintraub
Globe Correspondent / August 2, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

A 17-year-old Cambridge biotechnology firm is betting $35 million in new financing on the success of its budding gene therapy program. This spring, Genetix Pharmaceuticals reinvented itself as the developer of treatments for two rare and devastating genetic disorders. (Full article: 957 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass